Macrophages are polarized into two functionally distinct forms, M1 and M2, in response to different microenvironment. Tumor-associated macrophages (TAMs) generally have M2 phenotype and promote tumor progression. Few studies to date have described the infiltration of M2-polarized macrophages in ovarian cancer. We used two macrophages markers, CD68 and CD163, to analyze the expression of TAMs and to clarify the relationship between the M2 form and survival in advanced ovarian cancer. Clinical data of 110 patients with stages III-IV epithelial ovarian cancer at Sun Yat-sen University Cancer Center between 1999 and 2007 were retrospectively reviewed. Immunohistochemical staining of CD68 and CD163 was performed. Correlations between macrophage density and patient survival were analyzed.
Introduction
Ovarian cancer is the leading cause of death in patients with gynecologic malignancies. In 2008, there were approximately 225,500 new cases of ovarian cancer and 140,200 deaths worldwide (1) . In most cases, the disease at diagnosis is at an advanced stage. Even though most patients with advanced ovarian cancer obtain complete clinical response with cytoreductive surgery followed by platinum-based combination chemotherapy, approximately 75% of patients will eventually experience recurrent disease, and the overall prognosis is poor (2, 3) . It remains a challenge to identify patients in whom treatment is likely to fail. Reliable biomarkers for predicting long-term survival at diagnosis are urgently needed.
Accumulating evidence indicates that macrophages are important players in the process of tumorigenesis (4) (5) (6) . Macrophages are a heterogeneous population of cells derived from monocytes and polarized into two functionally distinct forms, M1 and M2, in response to different microenvironment (4, 7) . M1 macrophages produce high levels of inflammatory cytokines to limit tumor growth. In contrast, M2 macrophages release considerable amounts of immunosuppressive cytokines/chemokines and promote tumor growth and metastasis (4) .
Macrophages infiltrating the tumor microenvironment are defined as tumor-associated macrophages (TAMs) (7, 8) . It has been recognized that the presence of TAMs is an independent prognostic factor in several tumors. Increased numbers of TAMs, for example, have been reported to be associated with a poor prognosis in breast cancer (9) , bladder cancer (10) , gliomas (11) , and classic Hodgkin's lymphoma (12) . However, in studies on colon cancer (13) , prostate cancer (14) , and gastric cancer (15) , the infiltration of TAMs was correlated with an improved outcome. Thus, evidence on the association between TAMs and prognosis in cancer appear to be contradictory.
CD68, which is expressed by cells of the monocyte/ macrophage lineage, was frequently used as a marker to identify TAMs in previous studies (16) . However, it has been shown that CD68 is not a specific marker of cells of monocyte/macrophage derivation and is expressed by other stromal populations (17, 18) , which may to some extent explain the conflicting results observed on the relationship between TAMs and clinical prognosis in cancer. In addition, macrophages have two different polarized forms in different microenvironment, and the balance of these two forms determines the anti-or pro-tumor effects of the macrophage population. Therefore, the controversy with respect to the role of TAMs in the prognosis of patients with cancer may also be partly attributable to the heterogeneity of macrophages.
TAMs can be polarized in response to the particular microenvironment (18) . It has been accepted that TAMs generally have M2 phenotype and thus promote tumor growth (19, 20) . Investigation of the relationship between the M2 form macrophages and prognosis may facilitate our understanding of the real predictive value of TAMs in cancer. CD163 antigen is a member of the scavenger receptor cysteine-rich superfamily (21). It has been demonstrated that CD163 is restrictedly expressed in monocytes/macrophages and a more specific marker for cells of monocyte/macrophage origin than CD68 (17, 21) . Moreover, it has been shown that M2 macrophages highly express CD163 (19) , which as one of the markers to identify M2 macrophages has been reported on several tumors (22) (23) (24) (25) (26) (27) (28) . With respect to ovarian tumors, CD163 was also considered as a useful marker to evaluate the expression of M2 macrophages in the study by Kawamura et al. (29) . They found the number of CD163-positve M2 macrophages in borderline and malignant ovarian tumors were significantly higher than in benign ovarian tumors. However, limited studies describing the prognostic value of M2-polarized macrophages in ovarian cancer have been reported. In this study, we analyzed the expression of CD163-macrophages to evaluate the activation of M2-polarized macrophages in advanced ovarian cancer, and furthermore, to clarify the relationship between the M2 macrophages and survival in patients with advanced ovarian cancer.
Material and Methods

Patient Selection
We performed a retrospective review of the clinical records of all patients with epithelial ovarian cancer at Sun Yat-sen University Cancer Center between May 1999 and December 2007. Approval was granted from the institutional review board prior to the commencement of the study. Patients who met the following criteria were included: (i) a diagnosis of stage III-IV epithelial ovarian cancer; (ii) no anticancer or anti-inflammatory treatment prior to surgery; (iii) sufficient histological sections for immunohistochemical staining. One hundred and ten patients were eligible for inclusion. Patients' hospital records as well as survival data were collected from the database of our institute. Follow-up information was updated to October 2011. All specimens were obtained from the archives of formalin-fixed, paraffin-embedded tissue blocks in the Department of Pathology.
Immunohistochemistry
Representative formalin-fixed, paraffin-embedded sections were selected in order to perform immunohistochemical analysis. Four-μm thick tissue slides were dewaxed in xylene, and rehydrated through graded alcohol. This stage was followed by the inhibition of the endogenous peroxidase with 3% hydrogen peroxide for 10 minutes. The slides were then washed with phosphate buffered saline (PBS). An antigen retrieval process was performed in autoclave sterilizer with Ethylenediaminetetraacetic acid (EDTA) buffer, PH 8, for 20 minutes. The sections were then incubated with primary antibodies for 40 minutes at 37°C. The primary antibodies used were against CD68 (mouse monoclonal, NCL-L-CD68, 1:100 dilution, Leica-microsystems, Germany) and CD163 (mouse monoclonal, 10D6, 1:200 dilution, Novocastra, Newcastle, UK). After washed with PBS, the sections were incubated with the EnVision Detection (K5007, DAKO, Denmark) for 30 minutes at room temperature. The reaction was visualized Technology in Cancer Research & Treatment, Volume 12, Number 3, June 2013 using 3,3-diaminobenzidine (DAB) after a further wash in PBS. Finally, the sections were counterstained with Mayer's hematoxylin, dehydrated, and mounted. Tissue sections with macrophages that had previously stained positive were used as positive control, while a negative control was obtained by replacing the primary antibody with normal mouse IgG.
Immunohistochemistry Evaluation
Each immunostained specimen was evaluated over the whole section and the area with the highest number of positively stained cells (hot-spot area) was selected under low-power magnification (403). The positively stained cells in five consecutive high-power fields (HPF; 4003 magnification) in hotspot area were calculated to analyze macrophage infiltration. The positive expression of CD68 or CD163 was defined as a granular cytoplasm or a cytoplasmic and membrane staining pattern. The numbers of positive cells in each HPF were calculated by two independent pathologists in a blinded manner. The final TAMs' density for each case equated to an average of the results obtained by the two examiners and expressed as cell number/HPF.
Statistical Analysis
Statistical analysis was performed using SPSS 16.0 (SPSS, Chicago, IL, USA). The chi-square test was used to assess relationships between categorical variables, and the Mann-Whitney nonparametric test was used to compare continuous variables. Overall survival (OS) was defined as the period between the date of diagnosis and the date of death or, for living patients, the date of last contact. Progression-free survival (PFS) was defined as the time from diagnosis to the first appearance of progressive disease or death, whichever occurred first, or to the date of the last contact for patients who were alive and without progressive disease. Differences in survival were analyzed using the Kaplan-Meier method and compared using the log-rank test. A multivariate Cox proportional hazards regression model was used to identify independent prognostic factors. For comparisons, p , 0.05 was considered statistically significant.
Results
Patient Characteristics and Treatment
The clinical characteristics of the 110 patients were summarized in Table I . The median age was 53 years (range, 27-81 years). All patients underwent a complete staging operation or cytoreductive surgery. Sixty-four (58.2%) patients had optimal cytoreduction with residual disease that measured 1 cm, whereas 46 (41.8%) patients had suboptimal surgery with residual disease .1 cm. Primary chemotherapy mainly included 6-8 cycles of paclitaxel/docetaxel plus carboplatin/cisplatin. Combination of cyclophosphamide, bleomycin plus cisplatin/carboplatin was also used before 2003 when paclitaxel/docetaxel were not included in firstline chemotherapy for the disease in our department. Fourteen (12.7%) patients received various regimens, including 11 (10.0%) patients who experienced disease progression during primary chemotherapy, and three (2.7%) for reasons that were unclear.
Follow-up data were available in 108 patients, with information missing in two cases. There were 84 cases of recurrent disease, including 51 (51/84, 60.7%) platinum-sensitive recurrences with a chemotherapy-free interval .6 months, and 33 (33/84, 39.3%) platinum-resistant relapses with a chemotherapy-free interval ,6 months. In total, 54 (54/108, 50%) patients died of the disease. The median PFS and OS were 18.7 months and 37.6 months, respectively. The 3-year PFS and OS rates were 39.2% and 61.6%, respectively.
CD68 Expression
CD68-positive cells were mainly located in the peritumoral stroma. A few sections also displayed small areas with CD68-positive cells infiltrating tumor nests ( Figure 1 ). However, these areas were not hot-spot areas and thus were not used in calculations of the number of positive cells. The CD68-positive cell density was 39-242 cells/HPF (median 86 cells/HPF). The density of CD68-positive cells was significantly higher in patients with grade 2-3 tumors (p 5 0.015) than in those with grade 1 tumors. There was no significant relationship between the density of CD68-positive cells and age, histological type, or International Federation of Gynecology and Obstetrics (FIGO) stage. The type of recurrent disease (platinum-sensitive vs. platinum-resistant) was not correlated with CD68 expression (p 5 0.745) (Table II) .
CD163 Expression
CD163-positive cells were also predominantly found in the peritumoral stroma (Figure 1 ). Only a few cases containing scattered CD163-positive cells infiltrated in tumor nests were observed. The density of CD163-positive cells was 25-198 cells/HPF, with a median value of 76 cells/HPF. A significant increase in infiltration by CD163-positive cells was also observed in patients with grade 2-3 tumors (p 5 0.001), compared to those with grade 1 tumors. Age, histological type, FIGO stage, and the type of recurrent disease were not correlated with CD163 expression (Table II) .
Correlation of CD68 and CD163 Expression
In most cases, the number of CD163-positive cells was lower than the number of CD68 positive cells. Considering CD163 as one of the useful markers for identifying M2 macrophages, we anticipated that the ratio of CD163positive/CD68-positive cells would reflect the proportion of macrophages polarized to the M2 phenotype. In our data, the ratio of CD163/CD68 was 0.13-1.12 (median 0.64). The median value of this ratio was used as a cut-off point to classify patients into the high-CD163/CD68 ratio group or the low-CD163/CD68 ratio group. The high ratio group included more patients over the age of 45 years (60.5% vs. 12.5%, p , 0.001) and with grade 2-3 tumors (56.0% vs. 15.4%, p 5 0.006), than the low ratio group. There were more patients with platinum-resistant recurrences in the high-CD163/CD68 ratio group than in the low ratio group (72.7% vs. 47.1%, p 5 0.020). have M2 phenotype and thus promote tumor growth (19, 20) . Therefore, analysis of the correlation between survival and different polarized forms of macrophages, especially the M2 form, may provide new insights into understanding the prognostic significance of TAMs in cancer.
CD163 is a more specific marker for cells of monocyte/ macrophage origin than CD68, and used as one of the useful markers of distinguishing M2 macrophages from the M1 form (17, 21) . In the current study, we found that the density of CD163-positive macrophages as well as the ratio of CD163/CD68 were negatively independent predictors of PFS and OS, respectively, which indicated that activation of macrophages towards the M2-type correlated with worse prognostic impact in advanced ovarian cancer.
Our data were consistent with several studies, which reported the significance of the M2 form macrophages in cancer. In the report of Kurahara et al. (22) , the infiltration with a high number of CD163-positive macrophages was associated with a poor prognosis in pancreatic head cancer, however, no significant association was observed between the expression of CD68-positive macrophages and outcome. Komohara et al. (23) demonstrated that CD163-positive M2 macrophages contributed to a poor prognosis in patients with renal cell carcinoma, and CD163 may also help evaluate the M2 activation status of TAMs or the immunosuppressive conditions in the cancer microenvironment. In a study by Niino et al. (24) , cases of angioimmunoblastic T-cell lymphoma (AITL) with a higher density of CD163-positive macrophage infiltration
Survival and Prognostic Factors
We examined the relationship between the density of TAMs and patient survival. The median value of CD68-positive cell density was used as a cut-off point to classify patients into high-CD68 expression or low-CD68 expression groups. Similarly, the median value of CD163-positive cell density was used to classify patients into two CD163 expression groups. No significant difference was observed in PFS and OS between the high-and low-CD68 expression groups ( Figure 2) . In contrast, the 3-year PFS and OS rates for patients in the low-CD163 expression group (n 5 55) were 42.3% and 74.9%, which were significantly higher than the 3-year PFS (16.6%, p 5 0.003) and OS rates (48.0%, p 5 0.004) for patients in the high-CD163 expression group (n 5 53), respectively (Figure 2) . Similarly, we also found significantly improved 3-year PFS (49.8% vs. 11.0%, p , 0.001) and OS rates (77.4% vs. 45.0%, p , 0.001) in the low-CD163/CD68 ratio group (n 5 55) compared with the high ratio group (n 5 53) ( Figure 2 ). Multivariate regression analysis revealed that the density of CD163-positive cells as well as the ratio of CD163/CD68 were negatively prognostic factors for PFS and OS, respectively (Tables III and IV) .
Discussion
Although the prognostic significance of TAMs has been studied in several malignant tumors, it remains unclear whether infiltration of TAMs is associated with an improved or worse outcome (9) (10) (11) (12) (13) (14) (15) 30) . As mentioned previously, TAMs generally were found to have a worse overall survival. Furthermore, they also observed that an increasing ratio of CD163-positive to CD68-positive cells was associated with a poor outcome, which indicated that the ratio might be a useful marker for prognosis in AITL. Similarly, infiltration of CD163-positive M2 macrophages has also been reported to be associated with a worse prognosis in breast cancer (25) , rectal cancer (26), uveal melanoma (27) , and follicular lymphoma (28) .
Although CD163-positive M2 macrophages as a negative predictor for outcome has been observed in several studies, other data suggest the opposite. In colorectal cancer, CD163-positive macrophages were reported as increased in limited disease, and there was a trend for better survival in patients with a high CD163-positive cell infiltration (31) . In a study on nonsmall cell lung cancer (NSCLC), no association between M2 macrophage numbers and prognosis was observed, although M2 macrophages were 70% of the overall macrophage population (32) . In view of these conflicting results, more studies are needed to explore both the role of M2 form macrophages in cancer and the underlying molecular mechanism. We speculate that the differences observed in reported studies to date may be attributable to the differences in the biological activities of various tumors and patient populations.
Recently, an increasing body of evidence has suggested that epithelial ovarian cancer patients be divided into two groups designated type 1 and type 2 (33, 34) . Type 1 tumors tend to be low grade indolent neoplasms. In contrast, Type 2 tumors are extremely aggressive, rapidly growing, and high grade. In our study, high density of CD68-positive TAMs (p 5 0.015) and CD163-positive M2 macrophages (p 5 0.001), together with high-CD163/CD68 ratio (p 5 0.006) were associated with high tumor grade, respectively, which implied that high CD68 and CD163 expression, as well as high-CD163/CD68 ratio might correlated with type 2 ovarian tumors. Knowing that exposure to tumor-derived molecules causes TAMs to polarize into the M2 form and thus promote tumor progression, we speculated that higher grade tumors, characteristically more aggressive, recruit greater numbers of circulating monocytes/macrophages and drive them into M2 form macrophages. Nevertheless, this interpretation should be taken with caution owning to the small number of patients with grade 1 tumors (n 5 13, 11.8%) in our data. More needs to be understood about the correlation between tumor grade and the infiltration of M2 form macrophages.
In addition, we found that platinum-resistant recurrences were more prevalent in the high-CD163/CD68 ratio group than in the low ratio group (p 5 0.020), which implied that activation of macrophages towards the M2 phenotype might correlate with types of recurrent disease in ovarian cancer (platinum-resistant recurrence vs. platinum-sensitive). However, more studies are required to investigate the impact of macrophage activation phenotypes on types of recurrent ovarian cancer.
We identified the density of CD163-positive M2-polarized macrophages as a negatively independent predictor of survival in advanced ovarian cancer. This suggests that CD163-positive M2 macrophages may be important for targeted therapy in ovarian cancer. Reversing the immunosuppressive M2-polarized phenotype by immune manipulation may be an effective therapeutic strategy in ovarian cancer. However, this was a retrospective study and thus has limitations. The number of cases in our study was relatively small. In addition, although CD68 is commonly used as a marker to identify TAMs, it is not an exclusive marker for cells of monocyte/macrophage derivation (17, 18) . Thus, our results should be interpreted with caution.
In conclusion, we demonstrate that the infiltration of CD163positive M2 macrophages as well as activation of macrophages towards the M2 phenotype may contribute to poor survival in advanced ovarian cancer.
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